SEC and FTC open two more investigations into Biogen’s controversial Alzheimer’s drug approval and marketing practices – Endpoints News

Regeneron R&D chief and co-founder George Yancopoulos has never been shy about touting the company’s research capabilities — or ambitions. But then, he’s also a standout in his field, someone who can back up the bold talk with the rep he has built for herding a blockbuster group of cash cow franchises through the pipeline.

During the big biotech’s quarterly update today, CEO Len Schleifer was on hand to tout their continued market growth for Eylea — a $5.8 billion behemoth with a Phase III readout looming for their 8 mg version — as well as the Sanofi-partnered Dupixent with a big boost from a Covid-19 antibody now sidelined by Omicron. But Yancopoulos stole the show, enthusiastically highlighting a range of efforts in the research group that has the potential to create game-changing medicines that can generate billions more for the company.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 132,000+ biopharma pros reading Endpoints daily — and it’s free.


Leave a Comment